Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis

References

• Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.
   PubMedGoogle Scholar
• Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170–181.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Ho HJ, Wu CY, et al. Infantile infection and antibiotic exposure in association with pediatric psoriasis development: a nationwide nested case-control study. J Am Acad Dermatol. 2020. DOI:10.1016/j.jaad.2020.12.014
   Google Scholar
• Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–176.
   PubMed Web of Science ®Google Scholar
• Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet. 1998;7(10):1537–1545.
   PubMed Web of Science ®Google Scholar
• Pouessel G, Ythier H, Carpentier O, et al. Childhood pustular psoriasis associated with panton-valentine leukocidin-producing Staphylococcus aureus. Pediatr Dermatol. 2007;24(4):401–404.
   PubMed Web of Science ®Google Scholar
• Haddock ES, Calame A, Shimizu C, et al. Psoriasiform eruptions during Kawasaki disease (KD): a distinct phenotype. J Am Acad Dermatol. 2016;75(1):69–76 e2.
   PubMed Web of Science ®Google Scholar
• Milavec-Puretic V, Mance M, Ceovic R, et al. Drug induced psoriasis. Acta Dermatovenerol Croat. 2011;19(1):39–42.
   PubMed Web of Science ®Google Scholar
• Bucalo A, Rega F, Zangrilli A, et al. Paradoxical psoriasis induced by anti-TNFalpha treatment: evaluation of disease-specific clinical and genetic markers. Int J Mol Sci. 2020;21(21). DOI:10.3390/ijms21217873
   PubMed Web of Science ®Google Scholar
• Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69(2):189–193.
   PubMed Web of Science ®Google Scholar
• Shah KN. Diagnosis and treatment of pediatric psoriasis: current and future. Am J Clin Dermatol. 2013;14(3):195–213.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. Pediatric psoriasis: an update. Ther Clin Risk Manag. 2009;5:849–856.
   PubMedGoogle Scholar
• Bonigen J, Phan A, Hadj-Rabia S, et al. Impact of sex and age on the clinical and epidemiological aspects of childhood psoriasis: data from a French cross-sectional multicentre study. Ann Dermatol Venereol. 2016;143(5):354–363.
   PubMed Web of Science ®Google Scholar
• Paller AS, Singh R, Cloutier M, et al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17(2):187–194.
   PubMed Web of Science ®Google Scholar
• Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30(4):424–428.
   PubMed Web of Science ®Google Scholar
• Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18(3):188–198.
   PubMed Web of Science ®Google Scholar
• Pourchot D, Chiaverini C, Bourrat E, et al. Tongue psoriasis: clinical aspects and analysis of epidemiological associations in 313 children, with a systematic literature review. Ann Dermatol Venereol. 2018;145(10):578–586.
   PubMed Web of Science ®Google Scholar
• Kittler NW, Cordoro KM. Pediatric psoriasis comorbidities. Skin Therapy Lett. 2020;25(5):1–6.
   PubMedGoogle Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint american academy of dermatology-national psoriasis foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
   PubMed Web of Science ®Google Scholar
• Aalemi AK, Hamdard AG, Chen H. Association of metabolic syndrome with pediatric psoriasis: a case-control study in Kabul, Afghanistan. Int J Dermatol. 2020;59(4):451–456.
   PubMed Web of Science ®Google Scholar
• Osier E, Wang AS, Tollefson MM, et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017;153(7):698–704.
   PubMed Web of Science ®Google Scholar
• Phan K, Lee G, Fischer G. Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: systematic review and meta-analysis. Pediatr Dermatol. 2020;37(4):661–669.
   PubMed Web of Science ®Google Scholar
• Umano GR, Pistone C, Tondina E, et al. Pediatric obesity and the immune system. Front Pediatr. 2019;7:487.
   PubMed Web of Science ®Google Scholar
• Hunjan MK, Maradit Kremers H, Lohse C, et al. Association between obesity and pediatric psoriasis. Pediatr Dermatol. 2018;35(5):e304–e5.
   PubMed Web of Science ®Google Scholar
• Blegvad C, Nybo Andersen AM, Groot J, et al. Clinical characteristics including cardiovascular and metabolic risk factors in adolescents with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1516–1523.
   PubMed Web of Science ®Google Scholar
• Paller AS, Schenfeld J, Accortt NA, et al. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297.
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Van Houten HK, Asante D, et al. Association of psoriasis with comorbidity development in children with psoriasis. JAMA Dermatol. 2018;154(3):286–292.
   PubMed Web of Science ®Google Scholar
• Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577–583.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Cassara E, et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis. 2012;15(4):414–418.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999–1002.
   PubMed Web of Science ®Google Scholar
• Brandon TG, Manos CK, Xiao R, et al. Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities. J Psoriasis Psoriatic Arthritis. 2018;3(4):131–136.
   PubMedGoogle Scholar
• Zisman D, Gladman DD, Stoll ML, et al. The Juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification, and outcomes. J Rheumatol. 2017;44(3):342–351.
   PubMed Web of Science ®Google Scholar
• Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54(11):3564–3572.
   PubMed Web of Science ®Google Scholar
• Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–636.
   PubMed Web of Science ®Google Scholar
• Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol. 2003;48(6):805–21; quiz 22–4.
   PubMed Web of Science ®Google Scholar
• Freeman HJ. Natural history and long-term clinical course of Crohn’s disease. World J Gastroenterol. 2014;20(1):31–36.
   PubMed Web of Science ®Google Scholar
• Freeman HJ. Application of the Vienna Classification for Crohn’s disease to a single clinician database of 877 patients. Can J Gastroenterol. 2001;15(2):89–93.
   PubMed Web of Science ®Google Scholar
• Blegvad C, Egeberg A, Tind Nielsen TE, et al. Autoimmune disease in children and adolescents with psoriasis: a cross-sectional study in Denmark. Acta Derm Venereol. 2017;97(10):1225–1229.
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Finnie DM, Schoch JJ, et al. Impact of childhood psoriasis on parents of affected children. J Am Acad Dermatol. 2017;76(2):286–9 e5.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–7 e1–2.
   Web of Science ®Google Scholar
• Randa H, Lomholt JJ, Skov L, et al. Health-related quality of life in adolescents with psoriasis: an interview-based study. Br J Dermatol. 2018;178(6):1404–1411.
   PubMed Web of Science ®Google Scholar
• Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6(12). DOI:10.3390/children6120133
   PubMed Web of Science ®Google Scholar
• Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485–492.
   PubMed Web of Science ®Google Scholar
• Kara T, Topkarci Z, Yilmaz S, et al. Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study. J Dermatolog Treat. 2019;30(2):129–134.
   PubMed Web of Science ®Google Scholar
• Bilgic A, Bilgic O, Akis HK, et al. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010;27(6):614–617.
   PubMed Web of Science ®Google Scholar
• Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001;45(1):72–76.
   PubMed Web of Science ®Google Scholar
• Bruins FM, Bronckers I, Groenewoud HMM, et al. Association between quality of life and improvement in psoriasis severity and extent in pediatric patients. JAMA Dermatol. 2020;156(1):72–78.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Buzney CD, Kim N, et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol. 2013;30(6):700–705.
   PubMed Web of Science ®Google Scholar
• Fotiadou C, Lazaridou E, Ioannides D. Management of psoriasis in adolescence. Adolesc Health Med Ther. 2014;5:25–34.
   PubMedGoogle Scholar
• Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–178.
   PubMed Web of Science ®Google Scholar
• Schneeweiss MC, Huang JT, Wyss R, et al. Serious infection risk in children with psoriasis on systemic treatment: a propensity score-matched population-based study. J Am Acad Dermatol. 2020;82(6):1337–1345.
   PubMed Web of Science ®Google Scholar
• Bronckers I, Paller AS, West DP, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384–392.
   PubMed Web of Science ®Google Scholar
• Bronckers I, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147–1157.
   PubMed Web of Science ®Google Scholar
• Holzenburg A, Engel A, Kessler R, et al. Rapid isolation of OmpF porin-LPS complexes suitable for structure-function studies. Biochemistry. 1989;28(10):4187–4193.
   PubMed Web of Science ®Google Scholar
• Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82(1):213–221.
   PubMed Web of Science ®Google Scholar
• Aslam N, Saleem H, Murtazaliev S, et al. FDA approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric/adolescents in moderate to severe psoriasis? A systematic review. Cureus. 2020;12(8):e9812.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251.
   PubMed Web of Science ®Google Scholar
• Kellen R, Silverberg NB, Lebwohl M. Efficacy and safety of ustekinumab in adolescents. Pediatric Health Med Ther. 2016;7:109–120.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–49.
   PubMed Web of Science ®Google Scholar
• Paller AS, Seyger MMB, Alejandro Magarinos G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–241.
   PubMed Web of Science ®Google Scholar
• Commons RJ, Smeesters PR, Proft T, et al. Streptococcal superantigens: categorization and clinical associations. Trends Mol Med. 2014;20(1):48–62.
   PubMed Web of Science ®Google Scholar
• Leung DY, Hauk P, Strickland I, et al. The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. Br J Dermatol. 1998;139(Suppl 53):17–29.
   PubMedGoogle Scholar
• Ezepchuk YV, Leung DY, Middleton MH, et al. Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes. J Invest Dermatol. 1996;107(4):603–609.
   PubMed Web of Science ®Google Scholar
• Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest. 1995;96(5):2106–2112.
   PubMed Web of Science ®Google Scholar
• Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol. 2012;188(10):5160–5165.
   PubMed Web of Science ®Google Scholar
• Groot J, Blegvad C, Nybo Andersen AM, et al. Tonsillitis and pediatric psoriasis: cohort and cross-sectional analyses of offspring from the Danish national birth cohort. J Am Acad Dermatol. 2020;82(3):666–674.
   PubMed Web of Science ®Google Scholar
• Groot J, Blegvad C, Nybo Andersen AM, et al. Presence of streptococci and frequent tonsillitis among adolescents with psoriasis. Br J Dermatol. 2021;184(4):758–759.
   PubMed Web of Science ®Google Scholar
• George SM, Karanovic S, Harrison DA, et al. Interventions to reduce Staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019;2019(10). DOI:10.1002/14651858.CD003871.pub3
   Google Scholar
• Nguyen QD, Starling CT, Hebert AA. The use of TNFalpha inhibitors in treating pediatric skin disorders. Paediatr Drugs. 2020;22(3):311–319.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–7 e1–3.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63(5):769–774.
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu J, Wang J, et al. Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. AAPS J. 2019;21(5):91.
   PubMed Web of Science ®Google Scholar
• Corica D, Romano C. Biological therapy in pediatric inflammatory bowel disease: a systematic review. J Clin Gastroenterol. 2017;51(2):100–110.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75(1):30–42.
   PubMed Web of Science ®Google Scholar
• Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–67.
   PubMed Web of Science ®Google Scholar
• Bishop C, Simon H, Suskind D, et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016;63(3):348–351.
   PubMed Web of Science ®Google Scholar
• Chavannes M, Martinez-Vinson C, Hart L, et al. Management of paediatric patients with medically refractory Crohn’s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13(5):578–584.
   PubMed Web of Science ®Google Scholar
• Bonomo L, De Moll EH, Li L, et al. Tumor necrosis factor inhibitor-induced psoriasis in a pediatric Crohn’s disease patient successfully treated with ustekinumab. J Drugs Dermatol. 2020;19(3):328–331.
   PubMed Web of Science ®Google Scholar
• Bertrand V, El Haite A, Carre D. Efficiency of ustekinumab in Crohn’s disease with severe psoriasiform rash induced by biotherapies in an adolescent. Pediatr Dermatol. 2017;34(4):e214–e5.
   PubMed Web of Science ®Google Scholar
• Rinawi F, Rosenbach Y, Assa A, et al. Ustekinumab for resistant pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(4):e34–5.
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712.
   PubMed Web of Science ®Google Scholar
• Oostveen AM, De Jager ME, Van De Kerkhof PC, et al. The influence of treatments in daily clinical practice on the children’s dermatology life quality index in juvenile psoriasis: a longitudinal study from the child-CAPTURE patient registry. Br J Dermatol. 2012;167(1):145–149.
   PubMed Web of Science ®Google Scholar
• Van Geel MJ, Maatkamp M, Oostveen AM, et al. Comparison of the dermatology life quality index and the children’s dermatology life quality index in assessment of quality of life in patients with psoriasis aged 16–17 years. Br J Dermatol. 2016;174(1):152–157.
   PubMed Web of Science ®Google Scholar
• Chakravorty S, Chaudhary NS, Brower KJ. Alcohol dependence and its relationship with insomnia and other sleep disorders. Alcohol Clin Exp Res. 2016;40(11):2271–2282.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Dubinsky M, Ruemmele FM, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(3):453–460.
   PubMed Web of Science ®Google Scholar
• Manceau H, Chicha-Cattoir V, Puy H, et al. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55(4):474–483.
   PubMed Web of Science ®Google Scholar
• Favia G, Limongelli L, Tempesta A, et al. Oral lesions as first clinical manifestations of Crohn’s disease in paediatric patients: a report on 8 cases. Eur J Paediatr Dent. 2020;21(1):66–69.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Guariso G. Crohn’s disease and growth deficiency in children and adolescents. World J Gastroenterol. 2014;20(37):13219–13233.
   PubMed Web of Science ®Google Scholar
• Behnam SM, Behnam SE, Koo JY. Smoking and psoriasis. Skinmed. 2005;4(3):174–176.
   PubMedGoogle Scholar
• Behnam SM, Behnam SE, Koo JY. Alcohol as a risk factor for plaque-type psoriasis. Cutis. 2005;76(3):181–185.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79(1):104–9 e8.
   PubMed Web of Science ®Google Scholar
• Singh P, Silverberg JI. Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis. Arch Dermatol Res. 2020;313(3):163–171.
   Web of Science ®Google Scholar
• Torres T, Henrique M, Oliveira H, et al. Management of psoriasis by family physicians: referral algorithm and shared management with dermatology. Acta Med Port. 2020. Epub PMID 32208131.
   Google Scholar
• Lin VW. Tough-skinned kids: identifying psychosocial effects of psoriasis and helping pediatric patients and families cope. J Pediatr Nurs. 2012;27(5):563–572.
   PubMed Web of Science ®Google Scholar